151 related articles for article (PubMed ID: 8102920)
1. The characterization of peritoneal and pleural exudate cells from malignant effusions.
Oka M; Yoshino S; Hazama S; Shimoda K; Suzuki T
Surg Today; 1993; 23(6):500-3. PubMed ID: 8102920
[TBL] [Abstract][Full Text] [Related]
2. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity.
Amirghofran Z; Sheikhi AK; Kumar PV; Saberi Firouzi M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):443-8. PubMed ID: 12200601
[TBL] [Abstract][Full Text] [Related]
3. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Kimura S; Ogura T; Monden Y
Chest; 1993 Jun; 103(6):1732-8. PubMed ID: 8404092
[TBL] [Abstract][Full Text] [Related]
4. [Clinical effects and immunological analysis of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion of gastric carcinoma].
Hazama S; Oka M; Yoshino S; Iizuka N; Wadamori K; Yamamoto K; Hirazawa K; Wang F; Ogura Y; Masaki Y
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1595-7. PubMed ID: 7574768
[TBL] [Abstract][Full Text] [Related]
5. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
6. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
[TBL] [Abstract][Full Text] [Related]
7. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
Chao TY; Hwang WS; Yeh MY
Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic analysis of nylon-wool-adherent suppressor cells that inhibit the effector process of tumour cell lysis by lymphokine-activated killer cells in patients with advanced gastric carcinoma.
Koyama S; Fukao K
J Cancer Res Clin Oncol; 1994; 120(4):240-7. PubMed ID: 7904606
[TBL] [Abstract][Full Text] [Related]
9. Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.
Mantovani G; Macciò A; Versace R; Pisano M; Lai P; Esu S; Ghiani M; Dessì D; Turnu E; Santona MC
J Mol Med (Berl); 1995 Aug; 73(8):409-16. PubMed ID: 8528743
[TBL] [Abstract][Full Text] [Related]
10. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
Ebihara T; Koyama S
Gan No Rinsho; 1990 Apr; 36(5):604-10. PubMed ID: 2325266
[TBL] [Abstract][Full Text] [Related]
11. [Natural killer (NK) and lymphokine-activated killer (LAK) activities of a patient recovered from bladder cancer, and the characteristics of LAK cells generated from lymphocyte subsets].
Komatsu F; Kihara K
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Apr; 18(2):197-206. PubMed ID: 7553054
[TBL] [Abstract][Full Text] [Related]
12. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
13. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
15. Functional and phenotypic characteristics of effusion-associated lymphoid cells cultured in the presence of either recombinant interleukin 2 or T-cell growth factor from malignant pleural and peritoneal effusions in patients with advanced carcinoma.
Ebihara T; Koyama S
Tohoku J Exp Med; 1990 Sep; 162(1):49-63. PubMed ID: 2077678
[TBL] [Abstract][Full Text] [Related]
16. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
Ebihara T; Fukao K; Koyama S
Cancer; 1990 Sep; 66(5):923-9. PubMed ID: 2167147
[TBL] [Abstract][Full Text] [Related]
17. Characterization of equine natural killer and IL-2 stimulated lymphokine activated killer cell populations.
Viveiros MM; Antczak DF
Dev Comp Immunol; 1999 Sep; 23(6):521-32. PubMed ID: 10512462
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.
Karimine N; Arinaga S; Inoue H; Nanbara S; Ueo H; Akiyoshi T
Clin Exp Immunol; 1994 Jun; 96(3):484-90. PubMed ID: 8004819
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
20. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
